Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
Heitz, F
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. [electronic resource] - Gynecologic oncology 02 2019 - 235-242 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1095-6859
10.1016/j.ygyno.2018.11.008 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carboplatin--administration & dosage
Carcinoma, Ovarian Epithelial--drug therapy
Double-Blind Method
Female
Humans
Indoles--administration & dosage
Middle Aged
Neoplasm Staging
Neoplasm, Residual--pathology
Paclitaxel--administration & dosage
Prognosis
Young Adult
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12. [electronic resource] - Gynecologic oncology 02 2019 - 235-242 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1095-6859
10.1016/j.ygyno.2018.11.008 doi
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Carboplatin--administration & dosage
Carcinoma, Ovarian Epithelial--drug therapy
Double-Blind Method
Female
Humans
Indoles--administration & dosage
Middle Aged
Neoplasm Staging
Neoplasm, Residual--pathology
Paclitaxel--administration & dosage
Prognosis
Young Adult